Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Collplant Holdings (CLGN)
NASDAQ:CLGN
Collplant Holdings (CLGN) Stock Price & Analysis
146 Followers
CLGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.22 - $7.88
Previous Close$4.86
Volume1.01K
Average Volume (3M)8.13K
Market Cap
$55.70M
Enterprise Value$31.95M
Total Cash (Recent Filing)$26.91M
Total Debt (Recent Filing)$3.16M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 22, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding11,452,672
10 Day Avg. Volume12,307
30 Day Avg. Volume8,126
Standard Deviation0.19
R-Squared0.00546
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.97
Price to Sales (P/S)5.06
Price to Cash Flow (P/CF)-5.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue182.55
Enterprise Value/Gross Profit3.56
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$11.00Price Target Upside126.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Collplant Holdings News
PremiumCompany Announcements
CollPlant Innovates with 200cc Bio-Printed Breast Implants
PremiumCompany Announcements
CollPlant Highlights Innovation Amidst Q1 Financials
PremiumCompany Announcements
CollPlant Biotechnologies’ Strong Financial and R&D Progress
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCollPlant had approximately $23.2M in cash and cash equivalents, which is believed to be sufficient to fund operations.
Innovative TechnologyCollPlant initiated a second preclinical study of human collagen-based breast implants, which are manufactured using innovative 3D printing technology.
Milestone Payments And RoyaltiesCollPlant remains eligible to receive additional milestone payments of up to $26M and is expected to receive royalties on sales from AbbVie upon commercialization.
Bears Say
EarningsFor FY23, the company reported total revenues of $11M, compared to the consensus estimate of $13.6M, and a net loss of $0.62 per diluted share, compared to the consensus estimated net loss of $0.35 per share.
Financial PerformanceFor 1Q24, the company reported total revenues of approximately $0.10M, compared to the consensus estimate of $0.41M.
Financial PerformanceFor 1Q24, the company reported a net loss of $0.37 per diluted share, compared to the consensus estimated net loss of $0.39 per share.
---
Ownership Overview
0.00%
Insiders
0.05% Mutual Funds
10.59% Other Institutional Investors
89.36% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CLGN FAQ
What was Collplant Holdings’s price range in the past 12 months?
Collplant Holdings lowest stock price was $4.22 and its highest was $7.88 in the past 12 months.
What is Collplant Holdings’s market cap?
Currently, no data Available
When is Collplant Holdings’s upcoming earnings report date?
Collplant Holdings’s upcoming earnings report date is Aug 22, 2024 which is in 31 days.
How were Collplant Holdings’s earnings last quarter?
Currently, no data Available
Is Collplant Holdings overvalued?
According to Wall Street analysts Collplant Holdings’s price is currently Undervalued.
Does Collplant Holdings pay dividends?
Collplant Holdings does not currently pay dividends.
What is Collplant Holdings’s EPS estimate?
Collplant Holdings’s EPS estimate is -$0.35.
How many shares outstanding does Collplant Holdings have?
Collplant Holdings has 11,454,512 shares outstanding.
What happened to Collplant Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Collplant Holdings?
Among the largest hedge funds holding Collplant Holdings’s share is ARK Investment Management LLC. It holds Collplant Holdings’s shares valued at N/A.
---
Collplant Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (126.20% Upside)
$11.00 (126.20% Upside)
Hedge Fund Trend
Decreased
By 235.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.79%
12-Months-Change
Fundamentals
Return on Equity
-27.60%
Trailing 12-Months
Asset Growth
-15.29%
Trailing 12-Months
Company Description
Collplant Holdings
CollPlant Biotechnologies Ltd. is a regenerative medicine company. It engages in the research, development, manufacture and marketing of medical products for tissue repair, initially for orthobiologics and advanced wound care markets. The company's products include VergenixSTR, VergenixFG, CollPlant Surgical Matrix. Collplant Holdings was founded by in June 2004 and is headquartered in Ness-Ziona, Israel.
---
CLGN Earnings Call
Q4 2024
0:00 / 0:00
---
CLGN Stock 12 Month Forecast
Average Price Target
$11.00
▲(126.20% Upside)
Technical Analysis
Best Analysts Covering CLGN
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-19.94%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.94% per trade.
---